Compare Bristol-Myers Squibb Co (BMY) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Walmart Stores Inc — how do they compare? Bristol-Myers Squibb Co trades at $59 (market cap $116.30B), while Walmart Stores Inc trades at $114.18 (market cap $904.83B). The key difference: Walmart Stores Inc is far larger — about 7.8× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | WMT | |
|---|---|---|
Market Cap | $116.30B | $904.83B |
Sector | Health | Consumer Staples |
52-Week High | $62.37 | $134.20 |
52-Week Low | $42.60 | $95.05 |
Enterprise Value | $152.24B | $968.28B |
Dividend Yield | 4.42% | 0.87% |
Volume | — | 5,675,288 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Walmart (WMT) trades at $114.78, up 0.77% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong revenue growth to $681.0B in 2025 and a rising net income margin of 2.85%. Analyst consensus is strongly bullish with a $142.10 price target, though technical indicators show resistance near $115. Recent news highlights operational expansions in drone delivery and AI tools, alongside competitive pressures as Amazon overtakes it on the Fortune 500.
The outlook for WMT is positive based on fundamental strength and analyst optimism, but near-term technical resistance and competitive risks warrant caution. Investment opportunity lies in its consistent earnings performance and dividend yield, while risks include market volatility and execution challenges in e-commerce growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
